These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 34328594)
41. A multi-faceted genotoxic network of alpha-synuclein in the nucleus and mitochondria of dopaminergic neurons in Parkinson's disease: Emerging concepts and challenges. Vasquez V; Mitra J; Wang H; Hegde PM; Rao KS; Hegde ML Prog Neurobiol; 2020 Feb; 185():101729. PubMed ID: 31863801 [TBL] [Abstract][Full Text] [Related]
42. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases. Atsmon-Raz Y; Miller Y ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553 [TBL] [Abstract][Full Text] [Related]
44. [Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease]. Qiao S; Luo JH; Jin JH Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):210-4. PubMed ID: 22499522 [TBL] [Abstract][Full Text] [Related]
45. The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson's disease. Sian-Hulsmann J; Riederer P J Neural Transm (Vienna); 2020 May; 127(5):749-754. PubMed ID: 32318880 [TBL] [Abstract][Full Text] [Related]
46. Targeting alpha-synuclein for the treatment of Parkinson's disease. Rohn TT CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285 [TBL] [Abstract][Full Text] [Related]
47. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. Tsigelny IF; Crews L; Desplats P; Shaked GM; Sharikov Y; Mizuno H; Spencer B; Rockenstein E; Trejo M; Platoshyn O; Yuan JX; Masliah E PLoS One; 2008 Sep; 3(9):e3135. PubMed ID: 18769546 [TBL] [Abstract][Full Text] [Related]
48. Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. Tsigelny IF; Sharikov Y; Wrasidlo W; Gonzalez T; Desplats PA; Crews L; Spencer B; Masliah E FEBS J; 2012 Mar; 279(6):1000-13. PubMed ID: 22251432 [TBL] [Abstract][Full Text] [Related]
49. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. Colla E; Jensen PH; Pletnikova O; Troncoso JC; Glabe C; Lee MK J Neurosci; 2012 Mar; 32(10):3301-5. PubMed ID: 22399752 [TBL] [Abstract][Full Text] [Related]
50. Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson's Disease Targeting Neuroinflammation. Chen CM; Yen CY; Chen WL; Lin CH; Wu YR; Chang KH; Lee-Chen GJ Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494411 [TBL] [Abstract][Full Text] [Related]
51. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. Mehra S; Sahay S; Maji SK Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581 [TBL] [Abstract][Full Text] [Related]
52. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Martinez Z; Zhu M; Han S; Fink AL Biochemistry; 2007 Feb; 46(7):1868-77. PubMed ID: 17253773 [TBL] [Abstract][Full Text] [Related]
53. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations. Sahay S; Ghosh D; Singh PK; Maji SK Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727 [TBL] [Abstract][Full Text] [Related]
54. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254 [TBL] [Abstract][Full Text] [Related]
55. Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy. Sultana Z; Paleologou KE; Al-Mansoori KM; Ardah MT; Singh N; Usmani S; Jiao H; Martin FL; Bharath MM; Vali S; El-Agnaf OM Neuroscience; 2011 Dec; 199():303-17. PubMed ID: 22056602 [TBL] [Abstract][Full Text] [Related]
56. α-Synuclein and Lewy pathology in Parkinson's disease. Kalia LV; Kalia SK Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807 [TBL] [Abstract][Full Text] [Related]
57. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease. Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272 [TBL] [Abstract][Full Text] [Related]
58. The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of α-synuclein in C. elegans. Bornhorst J; Chakraborty S; Meyer S; Lohren H; Brinkhaus SG; Knight AL; Caldwell KA; Caldwell GA; Karst U; Schwerdtle T; Bowman A; Aschner M Metallomics; 2014 Mar; 6(3):476-90. PubMed ID: 24452053 [TBL] [Abstract][Full Text] [Related]
59. Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis. Gadhe L; Sakunthala A; Mukherjee S; Gahlot N; Bera R; Sawner AS; Kadu P; Maji SK Biophys Chem; 2022 Feb; 281():106736. PubMed ID: 34923391 [TBL] [Abstract][Full Text] [Related]
60. Solid-state ¹³C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein α-Synuclein. Leftin A; Job C; Beyer K; Brown MF J Mol Biol; 2013 Aug; 425(16):2973-87. PubMed ID: 23583776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]